What is CMPX's current stock price?

CMPX (Compass Therapeutics, Inc.) is currently trading at $2.07 with a market cap of $286.3M.

What sector is Compass Therapeutics, Inc. in?

Compass Therapeutics, Inc. (CMPX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CMPX a good stock to buy?

Analysts have a Buy consensus on CMPX with a price target of $11.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CMPX Compass Therapeutics, Inc.

Healthcare

$2.07+7.25%ClosedMarket Cap: $286.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.07

P/S

0.00

EV/EBITDA

-3.32

DCF Value

$0.12

FCF Yield

-18.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-39.7%

ROA

-33.2%

ROIC

-38.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-18.3M	$—
Q4 null	$0.00	$-15.7M	$—
FY null	$0.00	$-66.5M	$—
Q3 null	$0.00	$-14.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.20

Target (Median)

$10.00

Target Range

$9.00 - $15.00

2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

Canaccord GenuityBuy

2026-04-28

CitizensMarket Outperform

2026-04-28

D. Boral CapitalBuy

2026-04-27

HC Wainwright & Co.Buy

2026-04-27

GuggenheimBuy

2026-03-24

Trading Activity

Insider Trades

View All

Lerner Neilofficer: Chief Accounting Officer

BuyThu Apr 30

Anderman Jonathanofficer: General Counsel

BuyThu Apr 30

Lerner Neilofficer: Chief Accounting Officer

SellWed Apr 29

Anderman Jonathanofficer: General Counsel

SellWed Apr 29

Schuetz Thomas J.director, officer: CHIEF EXECUTIVE OFFICER

SellTue Feb 10

Latest News

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer TranscriptSeeking Alpha · Mon Apr 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.67

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Peers